HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 5, May 2016 – Healthcare Systems & Policies in Asia       » Understanding Healthcare Policies in the Philippines: Cancer Care       » Young Innovators under 35       » Healthcare Cost Effectiveness in Singapore       » ASLAN Pharmaceuticals Opens China Office       » A Journey Inside the Human Body       » Treatment Brings New Hope for Patients Suffering From Fatal Lung Disease      
BIOBOARD - INSIDE INDUSTRY
Biametrics successfully finalizes feasibility study with MorphoSys in the area of high-throughput antibody screening
Biametrics GmbH and MorphoSys AG plan to further collaborate in the area of high-throughput antibody screening.

Biametrics performed a very successful screening study using MorphoSys' reagents and Biametrics' label-free microarray based instrumentation b-screen for the characterization of Fab fragment antigen interactions. The feasibility study clearly demonstrated the advantages of b-screen to speed up the overall antibody screening process using the microarray format. Recently, Biametrics launched their b-screen device for high-throughput biomolecular interaction screening/analysis.

"We are delighted to be collaborating with MorphoSys, a leader in the development of biotherapeutics," said Dr. Florian Pröll, Managing Director of Biametrics "We look forward to expand our collaboration in the field of biomolecular interaction analysis."

Biametrics' b-screen device enables the detection of these biomolecules in a high-density array format on microscope slide disposables. Thereby, no fluorescence labels are needed for read-out. This leads to minimized sample pre-treatment and reagent consumption. With this new optical detection method, it is possible to reduce the complexity of the conventional label-free assays while enhancing the throughput and maintaining precision and reliability.

"We have identified b-screen as an promising technology in the field of epitope mapping, and will now broaden our collaboration with Biametrics", added Dr. Markus Enzelberger, Senior VP, Head of Discovery Alliances & Technologies at MorphoSys AG.

The collaboration between MorphoSys AG as a globally established supplier of therapeutic antibodies and Biametrics as an aspiring technology company allows for a fast and successful development of such biopharmaceuticals. MorphoSys will continue the cooperation with Biametrics.

Source: B3C Newswire

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices and Digital Health Technology
July:
Water Technology
August:
Guest Editorial - Antibody Informatics In Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy